三氧化二砷载药微球治疗VX2肝肿瘤兔模型的效果分析

王文辉; 段旭华; 李浩; 李凤尧; 琚书光; 王满周; 任建庄; 韩新巍

doi:10.3969/j.issn.1001-5256.2020.12.018

三氧化二砷载药微球治疗VX2肝肿瘤兔模型的效果分析

DOI: 10.3969/j.issn.1001-5256.2020.12.018

郑州大学第一附属医院介入科

基金项目:

国家自然科学基金（81401494）；

详细信息

中图分类号: R735.7;R-332
计量
- 文章访问数: 4283
- HTML全文浏览量: 64
- PDF下载量: 71
- 被引次数: 0
出版历程
- 收稿日期: 2020-06-15
- 出版日期: 2020-12-20

Effect of arsenic trioxide-loaded CalliSpheres beads in the treatment of rabbits with VX2 liver tumor

Department of Interventional Radiology,The First Affiliated Hospital of Zhengzhou University

Research funding:

摘要

摘要:
目的观察经肝动脉导管化疗栓塞术（TACE）中应用载药栓塞微球（CB）加载三氧化二砷（CBATO）对兔VX2肝肿瘤的疗效。方法荷瘤兔采用数字表法随机分为4组:对照组（n=30）、CB组（n=30,空白微球栓塞）、CBATO组（n=30）、常规TACE（cTACE）组（n=30,三氧化二砷碘油栓塞）。各组分别在术后12 h、3 d、7 d、14 d各处死实验兔5只,采用免疫组织化学法检测残瘤区肿瘤细胞增殖指数和凋亡百分比。术后7 d时测量各组肿瘤坏死体积,并计算肿瘤细胞生长率和坏死率。各组随机抽取10只,用于生存期观察。计量资料多组间比较采用方差分析,进一步两两比较采用LSD-t检验;生存期以Kaplan-Meier生存分析法进行评估,采用log-rank进行检验。结果术后7 d,CBATO组肿瘤细胞生长率明显低于cTACE组、CB组、对照组（P值均<0. 05）;肿瘤坏死率明显高于其他3组（P值均<0. 05）。术后各时间点,CBATO组增殖指数和凋亡百分比与其他3组相比,差异均具有统计学意义（P值均<0. 05）。CBATO组、CB组、cTACE组及对照组中位生存时间...
- 肝肿瘤 /
- 载药微球 /
- 三氧化二砷 /
- 疾病模型,动物
Abstract:
Objective To investigate the effect of arsenic trioxide-loaded CalliSpheres beads( CBATO) in transarterial chemoembolization( TACE) in the treatment of rabbits with VX2 liver tumor. Methods A total of 120 tumor-bearing rabbits were divided into control group,CalliSpheres beads( CB) group( blank beads for TACE),CBATO group,and conventional TACE( cTACE) group( arsenic trioxide lipiodol for TACE) using a random number table,with 30 rabbits in each group. Five rabbits in each group were sacrificed at 12 hours and on days 3,7,and 14 after TACE,and immunohistochemistry was used to measure the proliferation index and apoptosis percentage of tumor cells in the residual tumor area. The tumor necrotic volume was measure on day 7 after TACE,and the growth rate and necrosis rate of tumor cells were calculated. Ten rabbits were randomly selected from each group for the observation of survival time. An analysis of variance was used for comparison of continuous data between multiple groups,and the least significant difference t-test was used for further comparison between two groups; the Kaplan-Meier survival analysis was used to evaluate survival time,and the log-rank test was used for comparison.Results On day 7 after TACE,the CBATO group had a significantly lower growth rate and a significantly higher necrosis rate of tumor cells than the cTACE group,the CB group,and the control group( all P < 0. 05). At each time point after TACE,there were significant differences in the proliferation index and apoptosis percentage of tumor cells between the CBATO group and the other three groups( all P < 0. 05).The median survival time was 26 days in the CBATO group,18. 5 days in the CB group,22 days in the cTACE group,and 15. 5 days in the control group,and the CBATO group had a significantly longer survival time than the other three groups( χ2= 3. 95,8. 99,and 13. 47,P =0. 049,P = 0. 003,and P < 0. 01). Conclusion CBATO has a better effect than cTACE and CB in the treatment of rabbits with VX2 liver tumor and can significantly improve tumor necrosis rate,promote the apoptosis of tumor cells,and prolong the survival time of experimental animals.
- liver neoplasms /
- drug-eluting beads /
- arsenic trioxide /
- disease models,animal

HTML全文

参考文献(17)

[1] FORNER A,GILABERT M,BRUIX J,et al. Treatment of intermediate-stage hepatocellular carcinoma[J]. Nat Rev Clin Oncol,2014,11(9):525-535.

[2] ZHAO GR,LI H,DUAN XH,et al. The loading,releasing and antitumor mechanism of arsenic trioxide loaded by Calli Spheresbeads[J]. Chin J Radiol,2019,53(8):737-741.(in Chinese)赵国瑞，李浩，段旭华，等．Calli Spheres载药栓塞微球对三氧化二砷的加载释放及抗肿瘤机制研究[J]．中华放射学杂志，2019,53(8):737-741.

[3] MALAGARI K,POMONI M,MOSCHOURIS H,et al. Chemoemboliz tion of hepatocellular carcinoma with hepasphere 30-60μm. safety and efficacy study[J]. Cardiovasc Intervent Radiol,2014,37(1):165-175.

[4] XING M,WEBBER G,PRAJAPATI HJ,et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma:Longitudinal prospective study[J]. J Gastroenterol Hepatol,2015,30(7):1167-1174.

[5] LI H,DUAN XH,HAN XW,et al. Pharmacokinetics of drugeluting beads loading arsenic trioxide in the treatment of rabbit VX2 liver tumour[J]. Chin J Radiol,2019,53(7):615-620.(in Chinese)李浩，段旭华，韩新巍，等．载药微球三氧化二砷治疗兔VX2肝肿瘤药代动力学研究[J]．中华放射学杂志，2019,53(7):615-620.

[6] DUAN XH,LI TF,ZHOU GF,et al. Transcatheter arterial embolization combined with radiofrequency ablation activates CD8(+)T-cell infiltration surrounding residual tumors in the rabbit VX2 liver tumors[J]. Onco Targets Ther,2016,9:2835-2844.

[7] DUAN XH,LI H,REN JZ,et al. Hepatic arterial chemoembolization with arsenic trioxide eluting callispheres microspheres versus lipiodol emulsion:Pharmacokinetics and intratumoral concentration in a rabbit liver tumor model[J]. Cancer Manag Res,2019,11:9979-9988.

[8] PESAPANE F,NEZAMI N,PATELLA F,et al. New concepts in embolotherapy of HCC[J]. Med Oncol,2017,34(4):58.

[9] SONG MJ,CHUN HJ,SONG DS,et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma[J]. J Hepatol,2012,57(6):1244-1250.

[10] YIN WL,LIAN J,XIAO SX,et al. Clinical effect of drug-eluting beads and conventional transcatheter arterial chemoembolization in treatment of unresectable liver cancer:A metaanalysis[J]. J Clin Hepatol,2019,35(6):1270-1275.(in Chinese)尹伟利，连佳，肖时湘，等．载药微球与传统碘化油经肝动脉化疗栓塞术治疗不可切除肝癌效果比较的Meta分析[J]．临床肝胆病杂志，2019,35(6):1270-1275.

[11] HONG K,KHWAJA A,LIAPI E,et al. New intra-arterial drug delivery system for the treatment of liver cancer:Preclinical assessment in a rabbit model of liver cancer[J]. Clin Cancer Res,2006,12(8):2563-2567.

[12] DUAN XH,JU SG,HAN XW,et al. Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients[J]. Eur Rev Med Pharmacol Sci,2020,24(3):1468-1480.

[13] LIU B,HUANG JW,LI Y,et al. Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis:A single-blind,randomized trial[J]. J Cancer Res Clin Oncol,2015,141(6):1103-1108.

[14] KIMURA H,WEISZ A,KURASHIMA Y,et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide:Control of hypoxia-inducible factor-1 activity by nitric oxide[J]. Blood,2000,95(1):189-197.

[15] TINGTING R,WEI G,CHANGLIANG P,et al. Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway[J]. Cancer Biol Ther,2010,10(3):251-257.

[16] LEW YS,BROWN SL,GRIFFIN RJ,et al. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown[J]. Cancer Res,1999,59(24):6033-6037.

[17] VIVEIROS P,RIAZ A,LEWANDOWSKI RJ,et al. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma(HCC)[J].Cancers(Basel),2019,11(8):1085.

施引文献

资源附件(0)

访问统计